Peds I (Pediatric Eplerenone Development Study I): a randomized, double-blind, placebo withdrawal, parallel group, dose-response study to evaluate the efficacy and safety of eplerenone in the treatment of hypertension in children
Latest Information Update: 24 Dec 2020
At a glance
- Drugs Eplerenone (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms PEDS-I
- Sponsors Pfizer
- 16 Apr 2010 Results published in Journal of Pediatrics.
- 30 Oct 2005 New trial record.